{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.6","upperLimit":"41.1","value":"22.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \\>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. Response rate will be defined as the proportion of all subjects with confirmed PR or CR according to RECIST 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 240mg IV + Ramucirumab 8mg/kg IV\n\nNivolumab: Nivolumab 240mg, IV over 30 minutes.\n\nRamucirumab: 8mg/kg, IV over 60 minutes.","id":"OG000","title":"Nivolumab + Ramucirumab"}],"paramType":"NUMBER","populationDescription":"Out of 34 patients, one patient was not evaluable for response after he withdrew from study because of generalized weakness one day after first infusion of ramucirumab and nivolumab.","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 23 months","title":"Response Rate","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}